Sign In
Buy CRSP
$52.08
+0.0600 (+0.115%)
At Close: Jun 03, 2026
CRISPR Therapeutics AG (CRSP) Declines More Than Market: Some Information for Investors
07:05pm, Thursday, 20'th Mar 2025
CRISPR Therapeutics AG (CRSP) closed at $41.17 in the latest trading session, marking a -1.84% move from the prior day.
2 No-Brainer Biotech Stocks to Buy Right Now
06:10pm, Wednesday, 19'th Mar 2025
Biotech is an area that may offer your portfolio growth today and earnings stability tomorrow. The idea is a biotech stock might soar as investors bet on the company's cutting-edge technology through
CRISPR Therapeutics Stock Trades Near 52-Week Low: Time to Buy or Sell?
11:31am, Wednesday, 19'th Mar 2025
The fall in CRSP stock can be attributed to a lack of pipeline updates. Despite securing approval for its first marketed product in early 2024, it is yet to record product sales.
3 Gene Therapy Stocks to Watch Amid Industry Turmoil
03:21pm, Tuesday, 18'th Mar 2025
Sarepta Therapeutics Inc (NASDAQ:SRPT) is down 23.2% to trade at $77.86 at last check, and earlier hit a 52-week low of $75.06.
CRISPR Therapeutics AG (CRSP) is Attracting Investor Attention: Here is What You Should Know
10:01am, Friday, 14'th Mar 2025
CRISPR Therapeutics (CRSP) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
CRISPR Therapeutics AG (CRSP) TD Cowen 45th Annual Healthcare Conference (Transcript)
03:28pm, Monday, 03'rd Mar 2025
CRISPR Therapeutics AG (NASDAQ:CRSP ) TD Cowen 45th Annual Healthcare Conference March 3, 2025 10:30 AM ET Company Participants Samarth Kulkarni - CEO Conference Call Participants Tyler Van Buren - TD
CRISPR Therapeutics AG (CRSP) is Attracting Investor Attention: Here is What You Should Know
10:00am, Monday, 03'rd Mar 2025
CRISPR Therapeutics (CRSP) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Prediction: CRISPR Therapeutics Will Beat the Market. Here's Why
07:00pm, Friday, 28'th Feb 2025
Explore the exciting world of CRISPR Therapeutics (CRSP 0.69%) with our expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into market trends a
3 Beaten-Down Biotech Stocks to Buy Before They Soar. Wall Street Is Predicting Jumps of 68% to 250%.
03:15am, Friday, 28'th Feb 2025
Investors looking for growth in recent times have piled into stocks in artificial intelligence and quantum computing. But these aren't the only areas that offer the potential for explosive revenue gro
CRISPR Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference
08:00am, Wednesday, 26'th Feb 2025
ZUG, Switzerland and BOSTON, Feb. 26, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious disea
CRISPR Therapeutics AG (CRSP) Is a Trending Stock: Facts to Know Before Betting on It
10:00am, Thursday, 20'th Feb 2025
Recently, Zacks.com users have been paying close attention to CRISPR Therapeutics (CRSP). This makes it worthwhile to examine what the stock has in store.
CRSP Stock Rises 25% in a Week: Time to Buy, Hold or Sell?
10:16am, Tuesday, 18'th Feb 2025
The rise in CRISPR Therapeutics' share price can be attributed to the better-than-expected Q4 results and a rating upgrade by a well-established financial services firm.
Crispr Therapeutics Q4 Earnings Review: Ignore The Lack Of Revenues, Buy The Future
11:06am, Thursday, 13'th Feb 2025
Crispr Therapeutics AG reported significant revenue declines in Q4 and FY24 due to reduced collaboration revenues, but maintains strong financial health with $298m cash and $1.6bn in marketable securi
Why CRISPR Therapeutics Stock Was a Massive Winner on Wednesday
06:37pm, Wednesday, 12'th Feb 2025
On Hump Day, investors piled into CRISPR Therapeutics (CRSP 9.29%) stock, sending its price more than 9% higher at the trading session's close. They were highly encouraged by the specialized healthcar
CRISPR Therapeutics Q4 Earnings and Revenues Surpass Estimates
10:36am, Wednesday, 12'th Feb 2025
CRSP reports encouraging fourth-quarter results. The commercial launch of the first CRISPR-based gene therapy, Casgevy, is progressing well.
